Skip to main content

Table 1 Patient and graft characteristics

From: Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant

Variable Haploidentical N = 89 Matched related N = 69 P
Age (years), median (range) 22 (4–51) 33 (7–61) <0.001
 Children, no. (%) 33 (37.1%) 7 (10.1%) <0.001
 Adult, no. (%) 56 (62.9%) 62 (89.9%)  
Male/female, no. 57/32 39/30 0.337
SAA/VSAA, no. 69/20 58/11 0.305
Disease course (months), median (range) 0.507
 Interval from SAA diagnosis to SCT 1.5 (1–4.0) 1.0 (1–3.0)
Previous transfusion
 Median units of RBC (range) 7.0 (0–30) 8.0 (2–34) 0.115
 Median units of PLT (range) 13.5 (0–90) 10.0 (2–90) 0.036
aECOG pre-SCT, median, (range) 1 (0–3) 1 (0–2) 0.568
Donor-patient sex match, no. (%) 0.042
 Male-male 40 (44.9%) 17 (24.6%)
 Male-female 19 (21.3%) 15 (21.7%)
 Female-male 19 (21.3%) 22 (31.9%)
 Female-female 11 (12.4%) 15 (21.7%)
Donor type, no. (%) <0.001
 Sibling 25 (28.1%) 69 (100%)
 Parent 57 (64.0%)
 Child 5 (5.6%)
bOthers 2 (2.2%)
HLA type, no (%) <0.001
 6/6 4 (4.5%) 69 (100%)
 5/6 6 (6.7%)
 4/6 21 (23.6%)
 3/6 58 (65.2%)
ABO matched, no. (%) 0.414
 Matched 49 (55.1%) 44 (63.8%)
 Minor mismatched 18 (20.2%) 13 (18.8%)
 Major mismatched 14 (15.7%) 10 (14.5%)
 Different 8 (9.0%) 2 (2.9%)
Graft type, no. (%) <0.001
 BM + PB 78 (87.6%) 43 (63.2%)
 BM only 9 (10.1%) 3 (4.4%)
 PB only 2 (2.2%) 22 (32.4%)
Median MNCs, ×10^8/kg (range) 9.9 (3.4–32.0) 10.5 (4.6–26.4) 0.817
Median CD34+ count, ×10^6/kg (range) 3.6 (0.5–18.8) 4.5 (1.5–30.2) 0.001
Median CD3+ count, ×10^8/kg (range) 1.8 (0.1–6.7) 2.1 (0.1–7.7) 0.530
Median CD4+ count, ×10^8/kg (range) 1.0 (0.1–3.5) 1.1 (0.1–5.0) 0.337
Median CD8+ count, ×10^8/kg (range) 0.7 (0.1–3.0) 0.8 (0.1–2.7) 0.147
Median follow-up among alive patients, mo. (range) 21.4 (7.1–47.6) 26.0 (7.5–47.6) 0.258
Neutrophil engraftment, median (range) 12 (9–20) 11 (8–19) 0.151
Platelet engraftment, median (range) 15 (6–91) 14 (7–36) 0.484
  1. BM bone marrow, PB peripheral blood, MNC mononuclear cell
  2. *Patient age, previous transfusion of platelet, donor-recipient sex match, graft type, and infused CD34 cells differed significantly between the two groups (P < 0.05). There were no other significances between group differences
  3. aECOG (Eastern Cooperative Oncology Group scale) is used to evaluate patients’ performance status
  4. bOther donor types were from cousins